论文部分内容阅读
目的:探讨草酸艾司西酞普兰联合小剂量奥氮平对抑郁症患者负性情绪及神经功能的影响。方法:前瞻性选取温州医科大学附属康宁医院2018年7月至2019年1月收治的抑郁症患者120例，采用随机数字表法分为观察组60例、对照组60例，观察组采用草酸艾司西酞普兰联合小剂量奥氮平治疗，对照组采用草酸艾司西酞普兰治疗，两组疗程均为2个月。比较两组临床疗效、相关量表评分、神经功能指标及不良反应。结果:观察组总有效率为85.0%(51/60)，显著高于对照组的63.3%(38/60)(χn 2＝7.350，n P＝0.007)。治疗2个月后，观察组简易智能精神状态量表、汉密尔顿焦虑量表、汉密尔顿抑郁量表评分分别为(12.58±1.34)分、(33.27±4.32)分、(36.72±4.93)分，均低于对照组的(16.93±1.46)分、(41.82±3.95)分、(47.61±5.09)分(n t＝17.003、11.304、11.904，均n P<0.001)；观察组脑源性神经营养因子为(33.26±3.52)μg/L，高于对照组的(28.27±3.43)μg/L(n t＝7.864，n P<0.001)；观察组S100B蛋白、髓鞘碱性蛋白、神经元特异性烯醇化酶水平分别为(0.76±0.09)μg/L、(5.16±0.97)μg/L、(4.63±1.21)μg/L，均低于对照组的(1.31±0.12)μg/L、(7.36±0.83)μg/L、(7.72±1.69)μg/L(n t＝13.348、11.505、28.402，均n P<0.001)。对照组、观察组不良反应发生率分别为10.0%(6/60)、13.33%(8/60)，两组不良反应发生率差异无统计学意义(χn 2＝0.323，n P＝0.570)。n 结论:草酸艾司西酞普兰联合小剂量奥氮平治疗抑郁症，疗效确切，可有效改善患者负性情绪及神经功能。“,”Objective:To investigate the effects of escitalopram oxalate combined with low dose olanzapine on negative emotion and neurological function in patients with depression.Methods:From July 2018 to January 2019, 120 depressive patients who admitted to the Affiliated Kangning Hospital of Wengzhou Medical University were prospectively selected and divided into two groups according to random number table method, with 60 cases in each group.The observation group was treated with escitalopram oxalate combined with low dose olanzapine, while the control group was treated with escitalopram oxalate.The clinical efficacy, related scale scores, neurological function indicators and adverse reactions were compared between the two groups.Results:The total effective rate in the observation group was 85.0%(51/60) at 2 months after treatment, which was significantly higher than 63.3%(38/60) in the control group(χn 2=7.350, n P=0.007). At 2 months after treatment, the scores of Mini mental state examination, Hamilton anxiety scale and Hamilton depression scale in the observation group were (12.58±1.34)points, (33.27±4.32)points, (36.72±4.93)points, respectively, which were lower than those in the control group [(16.93±1.46)points, (41.82±3.95)points, (47.61±5.09)points] (n t=17.003, 11.304, 11.904, all n P<0.001). At 2 months after treatment, the level of brain-derived neurotrophic factor in the observation group was (33.26±3.52)μg/L, which was higher than that in the control group [(28.27±3.43)μg/L](n t=7.864, n P<0.001). The S100B protein, myelin basic protein, neuron-specific enolase levels in the observation group were (0.76±0.09)μg/L, (5.16±0.97)μg/L, (4.63±1.21)μg/L, respectively, which were lower than those in the control group [(1.31±0.12)μg/L, (7.36±0.83)μg/L, (7.72±1.69)μg/L](n t=13.348, 11.505, 28.402, all n P<0.001). The incidences of adverse reactions in the control group and the observation group were 10.0%(6/60) and 13.3%(8/60), respectively, there was no statistically significant difference between the two groups(χn 2=0.323, n P=0.570).n Conclusion:Escitalopram oxalate combined with low dose olanzapine is effective in the treatment of depression.It can effectively improve the negative mood and neurological function of patients.